Trial Profile
Phase 2/3 Study of Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease
Status:
Suspended
Phase of Trial:
Phase II/III
Latest Information Update: 04 Jan 2023
Price :
$35
*
At a glance
- Drugs Upamostat (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors RedHill Biopharma
- 03 Jan 2023 Primary endpoint (Part B - Comparison between upamostat and placebo in time to recovery from symptomatic illness.) has been met, according to a RedHill Biopharma media release.
- 03 Jan 2023 According to a RedHill Biopharma media release, results from this trial were published in the peer-reviewed International Journal of Infectious Diseases.
- 03 Jan 2023 Results published in the RedHill Biopharma Media Release.